Answers are grounded in this paper and cite their sources.
Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness. The first-line therapy is anti-vascular endothelial growth factor (anti-VEGF) agents delivered by intravitreal injection. Ionising radiation mitigates key pathogenic processes underlying nAMD, and therefore has therapeutic potential. STAR aimed to assess whether stereotactic radiotherapy (SRT) reduces the number of anti-VEGF injections required, without sacrificing visual acuity.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: